These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32198958)

  • 21. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
    Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
    Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice.
    Liévens JC; Woodman B; Mahal A; Spasic-Boscovic O; Samuel D; Kerkerian-Le Goff L; Bates GP
    Neurobiol Dis; 2001 Oct; 8(5):807-21. PubMed ID: 11592850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential electrophysiological and morphological alterations of thalamostriatal and corticostriatal projections in the R6/2 mouse model of Huntington's disease.
    Parievsky A; Moore C; Kamdjou T; Cepeda C; Meshul CK; Levine MS
    Neurobiol Dis; 2017 Dec; 108():29-44. PubMed ID: 28757327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images.
    Zhang J; Peng Q; Li Q; Jahanshad N; Hou Z; Jiang M; Masuda N; Langbehn DR; Miller MI; Mori S; Ross CA; Duan W
    Neuroimage; 2010 Feb; 49(3):2340-51. PubMed ID: 19850133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MR-spectroscopic findings in juvenile-onset Huntington's disease.
    Reynolds NC; Prost RW; Mark LP; Joseph SA
    Mov Disord; 2008 Oct; 23(13):1931-5. PubMed ID: 18759332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging of glutamate neurotransmitter alterations in Alzheimer's disease.
    Haris M; Nath K; Cai K; Singh A; Crescenzi R; Kogan F; Verma G; Reddy S; Hariharan H; Melhem ER; Reddy R
    NMR Biomed; 2013 Apr; 26(4):386-91. PubMed ID: 23045158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease.
    Sturrock A; Laule C; Decolongon J; Dar Santos R; Coleman AJ; Creighton S; Bechtel N; Reilmann R; Hayden MR; Tabrizi SJ; Mackay AL; Leavitt BR
    Neurology; 2010 Nov; 75(19):1702-10. PubMed ID: 21060093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glutamate-weighted CEST (gluCEST) imaging for mapping neurometabolism: An update on the state of the art and emerging findings from in vivo applications.
    Cember ATJ; Nanga RPR; Reddy R
    NMR Biomed; 2023 Jun; 36(6):e4780. PubMed ID: 35642353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expanded neurochemical profile in the early stage of Huntington disease using proton magnetic resonance spectroscopy.
    Adanyeguh IM; Monin ML; Rinaldi D; Freeman L; Durr A; Lehéricy S; Henry PG; Mochel F
    NMR Biomed; 2018 Mar; 31(3):. PubMed ID: 29315899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease.
    Andreassen OA; Dedeoglu A; Ferrante RJ; Jenkins BG; Ferrante KL; Thomas M; Friedlich A; Browne SE; Schilling G; Borchelt DR; Hersch SM; Ross CA; Beal MF
    Neurobiol Dis; 2001 Jun; 8(3):479-91. PubMed ID: 11447996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impaired Replenishment of Cortico-Striatal Synaptic Glutamate in Huntington's Disease Mouse Model.
    Buren C; Tu G; Raymond LA
    J Huntingtons Dis; 2020; 9(2):149-161. PubMed ID: 32310183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. pH as a biomarker of neurodegeneration in Huntington's disease: a translational rodent-human MRS study.
    Chaumeil MM; Valette J; Baligand C; Brouillet E; Hantraye P; Bloch G; Gaura V; Rialland A; Krystkowiak P; Verny C; Damier P; Remy P; Bachoud-Levi AC; Carlier P; Lebon V
    J Cereb Blood Flow Metab; 2012 May; 32(5):771-9. PubMed ID: 22373643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease.
    Reynolds NC; Prost RW; Mark LP
    Brain Res; 2005 Jan; 1031(1):82-9. PubMed ID: 15621015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
    Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
    Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolite differences between glutamate carboxypeptidase II gene knockout mice and their wild-type littermates after traumatic brain injury: a 7-tesla
    Wu W; Xu S; Wang J; Zhang K; Zhang M; Cao Y; Ren H; Zheng D; Zhong C
    BMC Neurosci; 2018 Nov; 19(1):75. PubMed ID: 30458729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
    Ferrante RJ; Andreassen OA; Jenkins BG; Dedeoglu A; Kuemmerle S; Kubilus JK; Kaddurah-Daouk R; Hersch SM; Beal MF
    J Neurosci; 2000 Jun; 20(12):4389-97. PubMed ID: 10844007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory.
    Taylor-Robinson SD; Weeks RA; Bryant DJ; Sargentoni J; Marcus CD; Harding AE; Brooks DJ
    Mov Disord; 1996 Mar; 11(2):167-73. PubMed ID: 8684387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.